RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy-Reference-Cited by-同舟云学术

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy

Published:2019-07-24 Issue:1 Volume:19 Page:
ISSN:1471-2490
Container-title:BMC Urology
language:en
Short-container-title:BMC Urol

Author:

Yang Zhenxing,Fu Bingqiang,Zhou Luqiang,Xu Jie,Hao Ping,Fang Zhenqiang

Funder

National Natural Science Foundation of China-Yunnan Joint Fund

Clinical research project key projects of Second Affiliated Hospital, Third Military Medical University

Publisher

Springer Science and Business Media LLC

Subject

Urology,Reproductive Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12894-019-0497-x.pdf

Reference20 articles.

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

2. Traboulsi SL, Kassouf W. Bladder cancer: a step closer to individualized treatment for bladder cancer. Nat Rev Urol. 2016;13(3):127–8.

3. Olivier Bosset P, Neuzillet Y, Paoletti X, Molinie V, Botto H, Lebret T. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer. Urol Oncol. 2015;33(1):20 e21–7.

4. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015;31(4):297–303.

5. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1):2186–90 quiz 2435.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neuronal DNA repair reveals strategies to influence CRISPR editing outcomes;2024-06-26

2. In vitro evolution and whole genome analysis to study chemotherapy drug resistance in haploid human cells;Scientific Reports;2024-06-18

3. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms;eBioMedicine;2023-09

4. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer;Oxidative Medicine and Cellular Longevity;2023-01-20

5. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms;2022-12-16